Latest Regulus Therapeutics Inc. Stories
LA JOLLA, Calif., Nov. 2, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the Australian Patent Office has recently granted claims in the 'Sarnow' patent series for microRNA-122 (miR-122) therapy in the treatment of hepatitis C viral (HCV) infections. The granted claims in Australia extend the reach of the Sarnow patent estate that already covers the use of an...
LA JOLLA, Calif., Oct. 24, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, will host this week a webinar that focuses on the potential of microRNA-33 as a target for the treatment of atherosclerosis. The discussion will involve pre-clinical research findings that demonstrate microRNA-33's key role in cholesterol homeostasis and fatty acid metabolism. These findings were published...
LA JOLLA, Calif., Sept. 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the presentation of recent advances in its microRNA therapeutic preclinical programs for the treatment of metabolic diseases and cancer. Specifically, Neil W. Gibson, Ph.D., Regulus' chief scientific officer will provide updates on the company's programs targeting microRNA-33 and microRNA-21...
LA JOLLA, Calif., July 20, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. This selection represents another significant milestone for Regulus in its microRNA alliance with GSK, which is focused on the discovery and...
LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB). The addition of Dr. Hannon, a researcher whose work has involved the molecular identification and characterization of the microRNA pathway, increases SAB membership to six pioneers in this area of scientific...
LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication in Nature of new pre-clinical data in mice about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a collaborative study performed by Regulus,...
LA JOLLA, Calif., June 6, 2011 - Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced publication in the Journal of Clinical Investigation of new pre-clinical data in mice on the antagonism of microRNA-33 (miR-33). The study, performed with collaborators at NYU Langone Medical Center, demonstrated that antagonism of miR-33 with proprietary chemically modified anti-miR oligonucleotides can...
CARLSBAD, Calif., Feb. 28, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2010 financial results and reviewed the highlights of the year. Isis improved upon its 2010 financial guidance with a pro forma net operating loss (NOL) of $36.2 million, which is significantly better than the mid to high $40 million range pro forma NOL the Company projected. Isis also exceeded its cash guidance by ending 2010 with $472.4 million of cash, cash equivalents and...
CARLSBAD, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2010. The Company finished the third quarter of 2010 with a pro forma net operating loss (NOL) of $6.0 million and $23.1 million for the three and nine months ended September 30, 2010, respectively, compared to a pro forma net operating loss of $6.9 million and $6.1 million for the same periods in 2009. On a GAAP...
CARLSBAD, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009....
